Navigation Links
iBioLaunch™ Technology Successfully Applied to Modified C1 Inhibitor
Date:11/17/2011

NEWARK, Del., Nov. 17, 2011 /PRNewswire/ -- iBio, Inc. (NYSE AMEX: IBIO) today announced that it successfully used its proprietary iBioLaunch technology to produce full length as well as a modified form of C1 esterase inhibitor in green plants.

Plasma-derived C1 esterase inhibitor is an Orphan Drug approved by the FDA to treat or prevent the symptoms of hereditary angioedema (HAE), an inherited disorder caused by low levels of C1 esterase inhibitor that causes swelling of the face, hands, feet, throat, stomach, bowels, or sexual organs. Annual global sales of HAE treatments are expected to exceed $1 billion as new treatment options penetrate the market. Additionally, C1 esterase inhibitors are the subject of multiple research programs investigating their potential use in the treatment of other inflammatory diseases.

iBio expects the properties of its iBioLaunch-produced C1 inhibitors to be useful in the treatment of HAE and other inflammatory disorders and expects to partner the products for clinical development as part of its commercial collaboration and licensing strategy.

C1 esterase inhibitor is a protease inhibitor involved in regulation of the complement pathway.  The expression of recombinant C1 esterase inhibitor in plants using the iBioLaunch expression platform was undertaken to provide an alternative to the current method of production that involves purification from human donor plasma.  Although therapeutic proteins purified from human plasma are tested for the absence of known pathogenic viruses, recombinant production of such proteins in a plant system that does not utilize any animal products can further reduce risk.

"These results continue the successful application of iBio's technology for the production of therapeutic proteins in plants, and further confirm the flexibility and speed of this technology when applied
'/>"/>

SOURCE iBio, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. iBio Announces New US Patent for iBioLaunch™ Technology
2. InNexus Biotechnology Announces Launch of Large Scale Primate Study of DXL625
3. CardioWest™ Artificial Heart Approved For Highest Reimbursement in CMS History : Plus Up To $53,000 New Technology Add-on Payments
4. Yongye Biotechnology International Retains CCG Investor Relations
5. William F. Prendergast Named One of the Top IP Lawyers in Nanotechnology
6. John Grisham Joins Focused Ultrasound Surgery Foundation Board, Citing Novel Technologys Potential to Help Millions of Patients
7. Yongye Biotechnology International Announces Conference Call to Discuss Second Quarter 2008 Results
8. [video] Jacques Tizabi, CEO of Universal Detection Technology Discusses Latest Purchase Order on WallSt.nets 3-Minute Press Show
9. Yongye Biotechnology International Announces Second Quarter Results
10. BeaconEquity.com Issues Trade Alerts on Biotechnology Stocks: ELN, PFE, AMGN, DNA, BIIB, GILD
11. ArunA Biomedical Announces Exclusive Worldwide Technology Licensing Agreement to Commercialize Human Embryonic Stem Cell Derived Mesenchymal Cells
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/22/2014)... , Dec. 22, 2014  Alternative Energy & ... it has signed a letter of intent to ... developed and patented a nanotechnology-based development platform used ... that enable rapid on-site collection and testing to ... health issues in an immediate, non-invasive and cost-effective ...
(Date:12/22/2014)... December 22, 2014 The ... publication of original research, reviews and editorials addressing ... clinical practice, today published a provocative article exploring ... development, progression and potential treatment of prostate cancer. ... research and proposes the possibility that there could ...
(Date:12/19/2014)... and Hershey, PA (PRWEB) December 19, 2014 ... BJCT), a leading developer and manufacturer of needle-free ... into an agreement with Immunomic Therapeutics, Inc. (“ITI”) ... needle-free injection device with its LAMP™ vaccine platform. ... option for an exclusive Worldwide license to the ...
(Date:12/19/2014)... Ill. , Dec. 19, 2014 Naurex ... develop novel drugs for diseases of the central nervous ... president and chief executive officer, will present at the ... Riedel,s presentation will take place at 3:00 p.m. PST ... Francis in San Francisco, Calif. ...
Breaking Biology Technology:ALNE Announces Intention To Acquire BioTechPharma 2Prostate Cancer Experts Dissect the Role of Follicle-stimulating Hormone in the Development, Progression and Potential Treatment of Prostate Cancer 2Prostate Cancer Experts Dissect the Role of Follicle-stimulating Hormone in the Development, Progression and Potential Treatment of Prostate Cancer 3Prostate Cancer Experts Dissect the Role of Follicle-stimulating Hormone in the Development, Progression and Potential Treatment of Prostate Cancer 4Bioject and Immunomic Therapeutics Enter into an Agreement for License of Needle-Free Technology for LAMP-vax Vaccines 2Bioject and Immunomic Therapeutics Enter into an Agreement for License of Needle-Free Technology for LAMP-vax Vaccines 3Naurex to Present at 33rd Annual J.P. Morgan Healthcare Conference 2
... , , , There is obviously no single , ... amplifications. For example, , depending on the length and sequence ... can differ from each other. Finding the optimal or the , ... and efficient amplification of a specific target. , ...
... Using Eppendorf Mastercycler gradient , , , , ... NPC Laboratory, Institute of Postgraduate Studies and Research, University , of Malaya, Kuala Lumpur, Malaysia , , ... , , ... , , ...
... Plant RNA, Using the Eppendorf Perfect ... , , , Sonja Vorwerk and ... Zchtungsforschung, Carl-von-Linn , Weg 10, 50829 Cologne, Germany , ... , Barbro Patterson, Eppendorf AG, Germany , ...
Cached Biology Technology:PCR Optimization 2PCR Optimization 3Amplification of Epstein-Barr Virus Exon C with Difficult Primers , Using Eppendorf Mastercycler gradient 2Amplification of Epstein-Barr Virus Exon C with Difficult Primers , Using Eppendorf Mastercycler gradient 3Amplification of Epstein-Barr Virus Exon C with Difficult Primers , Using Eppendorf Mastercycler gradient 4Amplification of Epstein-Barr Virus Exon C with Difficult Primers , Using Eppendorf Mastercycler gradient 5Simple and Rapid Isolation of Plant RNA, Using the Eppendorf Perfect RNA, Eukaryotic, Maxi Kit 2Simple and Rapid Isolation of Plant RNA, Using the Eppendorf Perfect RNA, Eukaryotic, Maxi Kit 3Simple and Rapid Isolation of Plant RNA, Using the Eppendorf Perfect RNA, Eukaryotic, Maxi Kit 4Simple and Rapid Isolation of Plant RNA, Using the Eppendorf Perfect RNA, Eukaryotic, Maxi Kit 5Simple and Rapid Isolation of Plant RNA, Using the Eppendorf Perfect RNA, Eukaryotic, Maxi Kit 6
(Date:12/19/2014)... DUBLIN , Dec. 18, 2014 Research ... announced the addition of the "iPhone 5S ... Technology Report" report to their offering. ... Following the acquisition of AuthenTec in July 2012, ... iPhone 5S. It is currently the only device ...
(Date:12/17/2014)... Dec. 15, 2014 Research and Markets ... of the "Samsung Galaxy S5 - Home ... to their offering. ... different sensing technology than the iPhone 5S, Samsung ... in its product. The Galaxy S5 ...
(Date:12/17/2014)... DUBLIN , Dec. 16, 2014 Research ... announced the addition of the "Global Chemical ... http://photos.prnewswire.com/prnh/20130307/600769 ... is the increasing demand for medical sensors in ... patient data for quick and correct diagnosis during ...
Breaking Biology News(10 mins):iPhone 5S Fingerprint Sensor - Apple/AuthenTec TMDR92 & Sapphire - Technology Report 2Samsung Galaxy S5 - Home Button Synaptics Fingerprint Sensor Technology Analysis 2Global Chemical Sensor Market 2015-2019: Key Vendors are Abbott Laboratories, Bayer, Hoffmann La-Roche, Johnson & Johnson, NGK Spark Plugs and Robert Bosch 2
... present its fifth annual Regional Policy Award to Ken ... Society,s upcoming conference in Portland, Oregon. The ESA award ... an outstanding record of informing political decision-making with ecological ... prestigious award to Ken Bierly for his long-term commitment ...
... in German . Excitation of neurons ... calcium and potassium through specific channels. Obviously, these channels were ... such channels could have evolved their selectivity has been a ... University of Vienna together with Scientists from Tel Aviv University ...
... older adults especially those who are frail low levels ... The randomized, nationally representative study found that older adults with ... death than people who had higher levels. Overall, people ... than those who were not frail. Frail adults with low levels ...
Cached Biology News:Ken Bierly of the Oregon Watershed Enhancement Board to receive ESA Regional Policy Award 2Ken Bierly of the Oregon Watershed Enhancement Board to receive ESA Regional Policy Award 3Ion selectivity in neuronal signaling channels evolved twice in animals 2Lower vitamin D could increase risk of dying, especially for frail, older adults 2
... high gel-strength agarose suitable for a wide ... constant field to Pulsed Field Gel Electrophoresis ... and exclusion limits, Multi ABgarose can effectively ... times. This in turn means reduced band ...
Mouse monoclonal [1.F.1] to Yersinia pestis F1 antigen ( Abpromise for all tested applications). Antigen: Purified F1 antigen of Y. pestis vaccine strain EB....
Rabbit polyclonal to L Kynurenine ( Abpromise for all tested applications). Antigen: Synthetic peptide L Kynurenine conjugated to a protein carrier. Entrez Gene ID: 8942 Swiss Protein ID...
Rabbit polyclonal to P5 ( Abpromise for all tested applications). entrezGeneID: 10954 SwissProtID: Q14554...
Biology Products: